KW-0761, Vorinistat, Clinical Trials, T-Cell Lymphoma

Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL

This study is ongoing, but not recruiting new patients.

The purpose of this study is to compare the progression free survival of KW-0761 versus vorinostat for subjects with relapsed or refractory CTCL.

Study Type:  Interventional

Study Design:        

Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Official Title:  Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 (Mogamulizumab) Versus Vorinostat in Subjects With Previously Treated Cutaneous T-Cell Lymphoma

Condition:  Cutaneous T-Cell Lymphoma                                                                              


Biological: KW-0761
Drug: Vorinostat                                                                            

Phase:  Phase 3

External Link: